A detailed history of Morgan Stanley transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,644,851 shares of NTLA stock, worth $56.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,644,851
Previous 2,545,022 3.92%
Holding current value
$56.5 Million
Previous $77.6 Million 6.23%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $2.38 Million - $3.27 Million
99,829 Added 3.92%
2,644,851 $72.8 Million
Q4 2023

Feb 13, 2024

SELL
$23.16 - $32.34 $12.6 Million - $17.7 Million
-545,919 Reduced 17.66%
2,545,022 $77.6 Million
Q3 2023

Nov 15, 2023

BUY
$31.62 - $45.78 $7.64 Million - $11.1 Million
241,734 Added 8.48%
3,090,941 $97.7 Million
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $6.7 Million - $8.92 Million
193,724 Added 7.3%
2,849,207 $116 Million
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $4.57 Million - $6.16 Million
137,333 Added 5.45%
2,655,483 $99 Million
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $32.8 Million - $61.9 Million
987,599 Added 64.53%
2,518,150 $87.9 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $15.9 Million - $21.1 Million
294,357 Added 23.81%
1,530,551 $85.7 Million
Q2 2022

Oct 27, 2022

SELL
$38.49 - $76.21 $2.26 Million - $4.48 Million
-58,805 Reduced 4.54%
1,236,194 $64 Million
Q2 2022

Aug 15, 2022

SELL
$38.49 - $76.21 $2.26 Million - $4.48 Million
-58,805 Reduced 4.54%
1,236,194 $64 Million
Q1 2022

Oct 27, 2022

BUY
$58.27 - $118.99 $3.43 Million - $7 Million
58,805 Added 4.76%
1,294,999 $94.1 Million
Q1 2022

May 13, 2022

SELL
$58.27 - $118.99 $13.3 Million - $27.2 Million
-228,254 Reduced 14.98%
1,294,999 $94.1 Million
Q4 2021

Feb 14, 2022

BUY
$100.76 - $138.36 $38 Million - $52.2 Million
377,214 Added 32.91%
1,523,253 $180 Million
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $152 Million - $203 Million
1,146,039 New
1,146,039 $154 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.63B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.